AI Article Synopsis
- The screening of donor blood for hepatitis B helped uncover that many post-transfusion hepatitis cases were caused by a previously unidentified agent called non-A, non-B, now known as hepatitis C virus.
- About 50% of individuals with hepatitis C go on to develop chronic liver disease, with 20% of that group eventually facing cirrhosis.
- The text discusses a patient who developed hepatitis C after receiving a blood transfusion due to obstetric complications, detailing the diagnostic process, clinical features, progression of the disease, and prevention strategies for hepatitis C.
Article Abstract
Screening of donor blood for hepatitis B led to recognition that most cases of post-transfusion hepatitis were due to an agent known as non-A, non-B. Until recently the causative agent for non-A, non-B hepatitis was identified, being denominated hepatitis C virus. It is estimated that one-half of patient with hepatitis C develop chronic liver disease, and 20% of this will develop cirrhosis. We describe a patient who due to obstetric complications received blood transfusion and during puerperium developed an icteric syndrome which was identified as C hepatitis. We review the diagnostic methodology, clinical characteristics, evolution and preventive measures of the C hepatitis.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Acute Hepatitis Related to Hepatitis E Virus Genotype 3f Infection in Brazil.
J Med Virol
November 2024
Laboratório de Gastroenterologia e Hepatologia Tropical, LIM-07, Instituto de Medicina Tropical, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, Brazil.
Article Synopsis
- * In group 1 (44 patients with acute hepatitis A), 4% tested positive for HEV IgM and 14.5% for IgG, while in group 2 (47 patients with non-A-C AH), these rates were 4.3% for IgM and 14.9% for IgG; only one sample from group 2 tested positive for HEV RNA.
- * The findings suggest HEV should be considered in non-A-C acute hepatitis cases, particularly as one patient with HEV recently traveled to a high-serop
An exploration of the optimal combination chemotherapy regimen based on neoadjuvant therapy containing pyrotinib for HER2-positive breast cancer: A multicenter real-world study.
Transl Oncol
January 2025
Department of Breast Surgery, Second Affiliated Hospital of Dalian Medical University, Dalian, China. Electronic address:
Background: The combination of pyrotinib (Py) with cytotoxic agents proved to be effective in early human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC). However, the optimal chemotherapy regimen is unknown. This study attempts to explore it from real-world research data.
View Article and Find Full Text PDFInvestigation of SEN virus prevalence in hemophilia patients.
New Microbes New Infect
December 2024
Infectious Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran.
Article Synopsis
- * A study in eastern Iran found that 58.2% of hemophilia patients had SENV, compared to 20% in healthy individuals, with the highest prevalence in type A and severe cases.
- * The results emphasize the need for ongoing monitoring of SENV in hemophilia patients due to its significant presence and potential health complications.
Metamizole outperforms meloxicam in sepsis: insights on analgesics, survival and immunomodulation in the peritoneal contamination and infection sepsis model.
Front Immunol
September 2024
Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Jena, Germany.
Background: Limited availability and side effects of opioids have led to an increased use of non-opioid analgesia in animal disease models. However, by affecting the immune-inflammatory reactions, analgesia may disrupt the resolution of the host inflammation and modulate the survival in septic animals. This study used a clinically relevant sepsis mouse model of peritoneal contamination and infection (PCI) to investigate the antinociceptive and anti-inflammatory properties of two non-opioid analgesics.
View Article and Find Full Text PDF[Not Available].
CMAJ
June 2024
Département de médecine (Phillips, Wheatley-Price), Université d'Ottawa, Ottawa, Ont.; Département de médecine (Leighl), Centre de cancérologie Princess Margaret, Université de Toronto, Toronto, Ont.; Département de médecine (Blais), Centre hospitalier de l'Université de Montréal, Université de Montréal, Montréal, Qc; Institut de recherche de l'hôpital d'Ottawa (Wheatley-Price), Ottawa, Ont.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!